Shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price target of $24.00 for the company, according to Zacks. Zacks has also given NuCana PLC Sponsored ADR an industry rank of 108 out of 265 based on the ratings given to related companies.

A number of research firms have issued reports on NCNA. William Blair began coverage on NuCana PLC Sponsored ADR in a research note on Monday. They set an “outperform” rating for the company. Cowen and Company began coverage on NuCana PLC Sponsored ADR in a research note on Monday. They set an “outperform” rating for the company. Citigroup Inc. began coverage on NuCana PLC Sponsored ADR in a research note on Monday. They set a “buy” rating and a $23.00 price target for the company. Finally, Jefferies Group LLC began coverage on NuCana PLC Sponsored ADR in a research note on Monday. They set a “buy” rating and a $25.00 price target for the company.

ILLEGAL ACTIVITY NOTICE: “Zacks: NuCana PLC Sponsored ADR (NCNA) Given Consensus Rating of “Strong Buy” by Brokerages” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/24/zacks-nucana-plc-sponsored-adr-ncna-given-consensus-rating-of-strong-buy-by-brokerages.html.

NuCana PLC Sponsored ADR (NASDAQ NCNA) traded down 0.79% during midday trading on Tuesday, reaching $13.80. 57,867 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $15.83 and its 200-day moving average price is $15.83. NuCana PLC Sponsored ADR has a one year low of $13.05 and a one year high of $19.95. The stock’s market cap is $438.99 million.

NuCana PLC Sponsored ADR Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Get a free copy of the Zacks research report on NuCana PLC Sponsored ADR (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.